Study guide
Hemostasis Testing
ASCP MLS Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Orientation To ASCP MLS Certification
Credential Purpose And Role ASCP BOC And Eligibility At A High Level MLS Versus MLS(ASCPi) Wording Application Fee And Transcript Result Basics CAT Exam Model Overview Study Plan From Content Guideline
2 Exam Format, CAT Scoring, And Score details
100 Questions And 2h30m Computer Adaptive Testing One-Best-Answer Multiple Choice Theoretical Versus Procedural Questions Scaled Score 100-999, Minimum 400 Score Notification Timing And Transcript Dependency
3 Blood Banking
Products And Components Blood Group Systems And Immunology Serologic And Molecular Testing Compatibility Testing And Transfusion Practice Physiology And Pathophysiology High-Yield Study Strategy
4 Chemistry
Carbohydrates, Lipids, Proteins, And Nitrogen Compounds Enzymes And Heme Derivatives Acid-Base, Blood Gases, And Electrolytes Endocrinology, Vitamins, And Nutrition Therapeutic Drug Monitoring And Toxicology Calculations And Correlation
5 Hematology And Hemostasis
Normal Hematopoiesis And Cell Morphology Anemia And RBC Disorders Leukocyte Disorders And Disease States Platelet And Coagulation Physiology Hemostasis Testing Smear, Analyzer, And Result Correlation
6 Microbiology
Preanalytic Specimen Handling Bacteriology Analytic Procedures Susceptibility And Organism Identification Logic Mycobacteriology, Virology, Parasitology, And Mycology Postanalytic Reporting Safety And Contamination Awareness
7 Urinalysis And Other Body Fluids
Physical And Chemical Urinalysis Microscopic Sediment Renal Physiology And Disease States CSF And Serous Fluids Body Fluid Cell Counts And Crystals Correlation And Preanalytic Issues
8 Immunology
Principles Of Immune Response Immune-System Diseases Infectious Disease Serology Transplantation And Compatibility Concepts Serologic Procedures And Test Methodology Interpretation Pitfalls
9 Laboratory Operations
Quality Assessment And Troubleshooting Safety Laboratory Mathematics Manual And Automated Methodology Instrumentation And Validation Management And Education Principles
10 Integrated Case Reasoning And Calculations
Correlating Patient Results To Disease States Applying Knowledge To New Facts Calculations And Units Procedural Decision-Making QA/QC In Case Questions Avoiding Memorization-Only Study
11 Practice Strategy And Remediation
Content Percentage Allocation CAT-Aware Practice Mindset Reviewing Misses By Domain Using The Official Guideline Before Third-Party Materials Transcript And Result Timing In Planning Final Remediation Cycles
12 Final Review And Exam-Day Readiness
Final-Week Schedule Timing And Pacing Score Expectations Result And Credential Next Steps Digital Badge And Documentation Post-Exam Actions Without Promises
Hemostasis Testing
Key Takeaways Explain This Topic AI
Coagulation specimens use 3.2% sodium citrate (light blue top) at a strict 9:1 blood-to-anticoagulant ratio.
PT is reported as INR to standardize warfarin monitoring across thromboplastin reagents.
A mixing study that corrects indicates factor deficiency; failure to correct indicates an inhibitor (e.g., lupus anticoagulant).
D-dimer is elevated in DIC and venous thromboembolism; a normal D-dimer helps rule out acute thrombosis.
Last updated: June 2026
Specimen Requirements (Preanalytical)
Coagulation testing is exquisitely sensitive to collection technique, and the MLS exam tests this heavily. The anticoagulant is 3.2% buffered sodium citrate in the light blue-top tube , drawn at a 9:1 ratio (9 parts blood to 1 part citrate). Citrate chelates calcium reversibly; calcium is added back during testing.
Common collection errors and their effects:
- Error Effect on PT/aPTT
- Underfilled (short draw) tube Excess citrate, falsely prolonged results
- Elevated hematocrit (>55%) Reduced plasma volume, falsely prolonged - requires citrate adjustment
- Heparin contamination from a line Falsely prolonged aPTT
- Clotted specimen Reject - consumes factors
Specimens are spun to platelet-poor plasma . Order of draw places the blue top after any sterile/blood-culture tube but before tubes with other additives, to avoid additive carryover. The classic teaching order of draw is: blood culture, then light blue (citrate) , then red/serum, then green (heparin), then lavender (EDTA), then gray (oxalate/fluoride). Drawing the citrate tube before EDTA prevents potassium-EDTA contamination that would chelate calcium and falsely prolong results. Specimens are generally stable about 4 hours at room temperature for PT/aPTT ; cold storage activates factor VII and platelets and is avoided.
The hematocrit correction matters because the volume of citrate is fixed for a normal plasma fraction; for a hematocrit above 55%, the citrate volume must be reduced using the formula citrate (mL) = 0.00185 x blood volume x (100 - Hct).
The Core Screening Tests
Prothrombin time (PT): thromboplastin + calcium added to plasma; measures the extrinsic and common pathways. Reported as the INR = (patient PT / mean normal PT)^ISI, which standardizes warfarin monitoring across reagents.
Activated partial thromboplastin time (aPTT): measures the intrinsic and common pathways; monitors unfractionated heparin .
Thrombin time (TT): prolonged by low/abnormal fibrinogen and by heparin; a normal reptilase time with a prolonged TT specifically implicates heparin contamination.
Fibrinogen (Clauss method): functional assay; reference roughly 200-400 mg/dL. Fibrinogen is also an acute-phase reactant, so it rises with inflammation and falls with consumption (DIC) or liver failure.
Reporting the INR rather than raw PT seconds is essential for warfarin. Because different thromboplastin reagents have different sensitivities, two labs could report different PT seconds for the same plasma; the INR normalizes this using each reagent's international sensitivity index (ISI) against the WHO reference, so a target INR of 2-3 means the same thing everywhere. The INR is only validated for stable warfarin therapy, not for liver disease or DIC, a subtlety the exam sometimes probes.
Mixing Studies
When the PT or aPTT is prolonged, a 1:1 mix of patient plasma with normal plasma sorts out the cause:
Corrects: points to a factor deficiency (the normal plasma supplies the missing factor).
Does not correct: points to an inhibitor such as a lupus anticoagulant or a specific factor inhibitor.
This logic is a frequent exam item - tie "corrects = deficiency, fails to correct = inhibitor" to memory. Some inhibitors are time- and temperature-dependent (notably a factor VIII inhibitor), so a properly performed mixing study includes an incubated phase at 37 C for 1-2 hours : a result that corrects immediately but prolongs after incubation suggests a slow-acting factor VIII inhibitor rather than a lupus anticoagulant. A lupus anticoagulant is phospholipid-dependent and is confirmed by phospholipid-neutralization tests; despite the prolonged aPTT in vitro, it paradoxically increases thrombosis risk in vivo.
D-dimer And Disseminated Intravascular Coagulation
D-dimer is a fibrin degradation product released when cross-linked fibrin is broken down by plasmin. It is elevated in venous thromboembolism, DIC, and recent surgery ; its high negative predictive value lets a normal D-dimer help rule out acute thrombosis.
Disseminated intravascular coagulation (DIC) is simultaneous widespread clotting and bleeding. The classic lab picture:
- Prolonged PT and aPTT
- Low fibrinogen (consumed)
- Low platelets (consumed)
- High D-dimer / FDPs
- Schistocytes on the smear (microangiopathic fragmentation)
The exam may contrast DIC with TTP/HUS , which also produce schistocytes and thrombocytopenia but show normal PT, aPTT, and fibrinogen because they are platelet-driven microangiopathies rather than consumptive coagulopathies. This coagulation-test pattern is the discriminator: abnormal PT/aPTT and low fibrinogen point to DIC, whereas normal coagulation tests with schistocytes and low platelets point to TTP/HUS. Liver disease can mimic DIC on screening tests but typically spares factor VIII, which is made outside the liver, so a normal factor VIII level favors liver disease over DIC.
Worked Example
A patient on warfarin has a PT/INR of 5.0 (target 2-3). The INR is far above the therapeutic window, indicating over-anticoagulation and a bleeding risk; the lab should ensure the result is verified and critical-value protocols followed. Because warfarin affects the vitamin-K factors, the PT/INR - not the aPTT - is the monitored test. A second scenario: a patient on unfractionated heparin has an aPTT at the upper end of the therapeutic range while the PT is only mildly affected - expected, because heparin potentiates antithrombin and is monitored by the aPTT (or anti-Xa assay), not the PT.
Low-molecular-weight heparin generally needs no routine monitoring but, when measured, uses an anti-factor-Xa assay rather than the aPTT, a distinction the exam likes to test.
Common Traps
Accepting a short-draw blue top - underfilling falsely prolongs results.
Reporting raw PT seconds for warfarin instead of the INR.
Confusing the heparin monitor (aPTT) with the warfarin monitor (PT/INR).